Results 181 to 190 of about 97,027 (306)

Serum Levels of Soluble Forms of Fas and FasL in Patients with Pancreatic and Papilla of Vater Adenocarcinomas. [PDF]

Cancers (Basel)
Anagnostoulis S, Bolanaki H, Asimakopoulos B, Ouroumidis D, Koutini M, Patris S, Tzimagiorgis I, Karayiannakis AJ.   +7 more
europepmc   +1 more source

Upregulation of the Fas Receptor Death-Inducing Signaling Complex after Traumatic Brain Injury in Mice and Humans [PDF]

, 2002
Jianhua Qiu, Michael J. Whalen, Pedro R. Löwenstein, Gary Fiskum, B. Fahy, Ribal Darwish, Bizhan Aarabi, Junying Yuan, Michael A. Moskowitz   +8 more
openalex   +1 more source

The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model

Journal of Clinical Laboratory Analysis, EarlyView.
Momelotinib, a selective small‐molecule inhibitor of JAK1/2 and the bone morphogenic protein receptor kinase activin A receptor type I (ACVR1), exerts its effects by inhibiting the overactivation of the BMP/ACVR1/SMAD signaling pathway. This inhibition reduces hepcidin production in hepatocytes, and reduces inflammation, aberrant cytokine signaling ...
Yue Zhang, Huiqin Zhang, Naibo Hu, Liping Yang, Yumei Liu, Liyan Yang, Xifeng Dong, Huaquan Wang   +7 more
wiley   +1 more source

RETRACTED: Wang et al. Mipu1 Protects H9c2 Myogenic Cells from Hydrogen Peroxide-Induced Apoptosis through Inhibition of the Expression of the Death Receptor Fas. <i>Int. J. Mol. Sci.</i> 2014, <i>15</i>, 18206-18220. [PDF]

Int J Mol Sci
Wang G, Jiang L, Song J, Zhou SF, Zhang H, Wang K, Xiao X.   +6 more
europepmc   +1 more source

Fas Receptor Activation by Endogenous Opioids Is A New Mechanism for Cardiomyopathy in Cirrhotic Rats. [PDF]

J Clin Exp Hepatol, 2017
Abbasi A, Faramarzi N, Khosravi M, Yazarloo F, Abbasi MA, Dehpour AR, Jahanzad I.   +6 more
europepmc   +1 more source

CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30− Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions [PDF]

, 2018
Lee K. Hong, Yu‐Hui Chen, Christof C. Smith, Stephanie A. Montgomery, Benjamin G. Vincent, Gianpietro Dotti, Barbara Savoldo   +6 more
openalex   +1 more source

Recurrence Rates in Paediatric Patients With Atopic Dermatitis: A Comparison Between Topical and Systemic Treatments

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic, relapsing skin condition that significantly affects children and their families. Treatment ranges from topical to systemic therapies, but evidence on long‐term recurrence following different treatment strategies in paediatric AD remains limited.
Frederikke Seeberg, Anne Sofie Frølunde, Mette Deleuran, Christian Vestergaard   +3 more
wiley   +1 more source

Peroxisome Proliferator-Activated Receptor α/δ/γ Activation Profile by Endogenous Long-Chain Fatty Acids. [PDF]

Int J Mol Sci
Honda A, Hosoda A, Kamichatani W, Ogasawara M, Miyazaki S, Kashiwagi N, Kamata S, Ishii I.   +7 more
europepmc   +1 more source

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
Rademikibart, a potent IL‐4Rα‐targeting antibody, achieved its primary endpoint as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2 trial. There is a need for AD treatment options with convenient dosing intervals.
Jonathan I. Silverberg, Emma Guttman‐Yassky, Raúl Collazo   +2 more
wiley   +1 more source

Colorectal Cancer: Differential Gene Expression and In Vitro Response to 5-Fluorouracil, Novel Fluoropyrimidine F10, and Potential Synergy with Lupeol. [PDF]

Int J Mol Sci
Thaker SD, Paredes J, Garai J, Martello LA, Gmeiner WH, Zabaleta J, Williams J.   +6 more
europepmc   +1 more source